Τόμος 3 (1985) – Τεύχος 1 – Άρθρο 7 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση – Volume 3 (1985) – Issue 1 – Article 7 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

P. NIKOLAIDIS, J. ZIKIDOU, P. TSOLKAS AND A. TOURKANTONIS

^{Α’ Παθολογική Κλινική Πανεπιστημίου Θεσ/νίκης, Νοσοκομείο Αχέπα, Θεσσαλονίκη}

2: 306-311 (1985)

PHARMAKON-Press: Epitheorese Klin. Farmakol. Farmakokinet.

2: 306-311 (1985)

To evaluate the clinical and microbiological efficacy and safety in the treat­ment of Nosocomial infections, moxalactam was given in 42 hospitalized patients (27 fe­males and 15 males) with a mean age 56.8 years suffering from lower respiratory tract infections (13), biliary tract infections (12), uri­nary tract infections (13), miscellaneous as pe­ritonitis (3), intraabdominal abscess (3), surgical wound infections (3) and septicaemia (1). In 23 patients various underling diseases predisposed to the development of infections. Pathogens included E. coli (9), klebsiella (7), Pseudomo­nas (8), Proteus species (5), Enterobacter (3), Bacteroides fragilis (1), Haemophilus species (2) and Staphylococcus species (3). In all patients moxalactam was given intravenously at mean dose 5.4 gr per day for 5 to 10 days. Clinical, laboratory and microbiological tests in all pa­tients were performed. Clinical response to moxalactam therapy was cure in 83.3% of the patients and pathogens were eradicated in 86.8%. The adverse reactions during therapy were mild and transient elevation of alkaline phosphatase and prolongation of prothrombin time. It is concluded that moxalactam is an effective antibiotic in the treatment of nosocomial infections especially due to Gram nega­tive organisms.

1. .Webber, A.J., Yoshida, T.: Moxalactam: The first of a new class of β-lactam antibiotics. Rev. Infect. Dis. 4 (suppl.): 496 (1982)
2. Gitehrist, M.J.R., Washington, J.A.: In vitro activity of moxalactam against anaerobic bacteria. Rev. Infect. Dis. 4 (suppl.): 511 (1982)
3. Goto, S.: In vitro end in vivo antibacterial activity of moxalactam an oxa-β-lactam antibiotic. Rev. infect. Dis. 4 (suppl,): 501 (1982)
4. Fisher, J.F., Carter, M.J., Parsons, J., Rissing, J.P.: Mo­xalactam (LΥ127935) in treatment of meningitis due to Gram negative bacilli. Antimicrob. Agents Chemother. 19: 218 (1981)
5. Giamarellou, H., Tsagarakis, J., Daikos, G.K.: Moxala­ctam in serious infections: Clinical, bacteriologic and pharmacokinetic studies. Rev. Infect. Dis. 4 (suppl.).: 629 (1982)